Skip to content
Peptigraph home

Mazdutide Phase 2 trial (NCT06124807)

A Phase 2, Parallel-Group, Double-Blind, 4-Arm Study to Investigate Weight Management With LY3305677 Compared With Placebo and in Adult Participants With Obesity or Overweight

Registry record checked

At a glance

Phase
Phase 2
Status
Completed
Enrolment
179
actual
Start
17 Nov 2023 (actual)
Primary completion
22 Jan 2025 (actual)
Sponsor
Eli Lilly and Company
Design

Arms and doses

NCT06124807 study arms
ArmTypeInterventionsDescription
3/6 Milligrams (mg) MazdutideExperimentalDrug: MazdutideParticipants received once-weekly subcutaneous Mazdutide with dose escalation until the target dose (3 or 6 mg) was achieved, starting at 1.5 mg from Weeks 0-3, followed by 3 mg from Weeks 4-31, then 6 mg from Weeks 32-48.
10 mg MazdutideExperimentalDrug: MazdutideParticipants received once-weekly subcutaneous Mazdutide with dose escalation until the target dose (10 mg) was achieved, starting at 1.5 mg from Weeks 0-3, followed by 3 mg from Weeks 4-7, 6 mg from Weeks 8-11, 8 mg from Weeks 12-15, and then 10 mg from Weeks 16-48.
16 mg MazdutideExperimentalDrug: MazdutideParticipants received once-weekly subcutaneous Mazdutide with dose escalation until the target dose (16 mg) was achieved, starting at 1.5 mg from Weeks 0-3, followed by 3 mg from Weeks 4-7, 6 mg from Weeks 8-11, 9 mg from Weeks 12-15, 12 mg from Weeks 16-19, and then16 mg from Weeks 20-48.
PlaceboPlacebo comparatorDrug: PlaceboParticipants received Mazdutide matched placebo subcutaneously once weekly from Weeks 0 to 48.
Endpoints

Primary endpoint

NCT06124807 primary outcomes
MeasureTime frame
Percent Change From Baseline in Body Weight at Week 32Baseline, Week 32
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT06124807 secondary outcomes
MeasureTime frame
Percent Change From Baseline in Body Weight at Week 48Baseline, Week 48
Change From Baseline in Body WeightBaseline, Week 32, Week 48
Mean Percentage of Participants Who Achieve ≥5% Body Weight ReductionBaseline, Week 32, Week 48
Mean Percentage of Participants Who Achieve ≥10% Body Weight ReductionBaseline, Week 32, Week 48
Change From Baseline in Body Mass Index (BMI)Baseline, Week 32, Week 48
Number of Participants With Treatment Emergent Anti-drug Antibodies (TE-ADAs)Baseline up to week 56
Pharmacokinetics (PK): Area Under the Curve (AUC) of Mazdutide at Steady StatePredose at Week 0, Week 4, Week 8, Week 12, Week 24, Week 32, Week 48; Post dose (2 to 6 hours after dosing) at Week 0, Week 12, Week 24
PK: Maximum Concentration (Cmax) of Mazdutide at Steady StatePredose at Week 0, Week 4, Week 8, Week 12, Week 24, Week 32, Week 48; Post dose (2 to 6 hours after dosing) at Week 0, Week 12, Week 24
Change From Baseline in Liver Fat Content (LFC) by Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) in Participants With Baseline LFC >=5%Baseline, Week 32, Week 48
Percent Change From Baseline in Liver Fat Content by MRI-PDFF in Participants With Baseline LFC >=5%Baseline, Week 32, Week 48
Change From Baseline in Liver Fat Content by MRI-PDFF in Participants With Baseline LFC >=10%Baseline, Week 32, Week 48
Percent Change From Baseline in Liver Fat Content by MRI-PDFF in Participants With Baseline LFC >=10%Baseline, Week 32, Week 48
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
75 Years
Results

Results

Results are posted on the registry. Open the ClinicalTrials.gov record for NCT06124807.

The US dose-range trial of mazdutide up to 16 mg

Adults without type 2 diabetes were randomised 3:2:3:3 to placebo or mazdutide at 3-6 mg, 10 mg or 16 mg weekly for 48 weeks.[2]

At 32 weeks bodyweight changed by -7.3%, -15.6% and -18.1% across the three mazdutide groups, against -0.9% with placebo.[2]

Discontinuation because of adverse events was most frequent on 16 mg, at 20%, mainly for gastrointestinal disorders.[2]

The 3-6 mg group stayed on 3 mg from week 4 to week 32 before escalating to 6 mg, to test 3 mg and 6 mg as maintenance doses.[2]

Sources

  1. 1A Phase 2, Parallel-Group, Double-Blind, 4-Arm Study to Investigate Weight Management With LY3305677 Compared With Placebo and in Adult Participants With Obesity or OverweightClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
  2. 2Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial.The lancet. Diabetes & endocrinology · 2026PMID 42628555Accessed 2 Oct 2026

Found an error? Report a correction.